F-18 FDG PET/CT Imaging in Normal Variants, Pitfalls and Artifacts in the Abdomen and Pelvis

Vangu, Mboyo-Di-Tamba; Momodu, Jaleelat I.

doi:10.3389/fnume.2021.826109

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Organs with naturally high glucose metabolism, such as the brain or liver, exhibit elevated FDG uptake. Moreover, benign conditions characterized by increased glycolysis also result in the accumulation of FDG in cells[ 17 - 21 ]. Consequently, FDG cannot be considered a selective agent for distinguishing between malignant and benign cells.…”

Section: F-18 Fdg Into Cellsmentioning

confidence: 99%

Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?

Lee,

Hwang

2024

World J Clin Cases

View full text Add to dashboard Cite

Since the inception of fluorine-18 fluorodeoxyglucose (F-18 FDG), positron emission tomography/computed tomography (PET/CT) utilizing F-18 FDG has become widely accepted as a valuable imaging modality in the field of oncology, with global prevalence in clinical practice. Given that a single Torso PET/CT scan encompasses the anatomical region from the skull base to the upper thigh, the detection of incidental abnormal focal hypermetabolism in areas of limited clinical interest is both feasible and not uncommon. Numerous investigations have been undertaken to delineate the distinctive features of these findings, yet the outcomes have proven inconclusive. The incongruent results of these studies present a challenge for physicians, leaving them uncertain about the appropriate course of action. This article provides a succinct overview of the characteristics of fluorodeoxyglucose, followed by a comprehensive discussion of the imaging findings and clinical significance associated with incidental focal abnormal F-18 FDG activity in several representative organs. In conclusion, while the prevalence of unrecognized malignancy varies across organs, malignancies account for a substantial proportion, ranging from approximately one-third to over half, of incidental focal uptake. In light of these rates, physicians are urged to exercise vigilance in not disregarding unexpected uptake, facilitating more assured clinical decisions, and advocating for further active evaluation.

show abstract

Section: F-18 Fdg Into Cellsmentioning

confidence: 99%

Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?

Lee,

Hwang

2024

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…Organs with naturally high glucose metabolism, such as the brain or liver, exhibit increased FDG uptake. Moreover, benign conditions with elevated glycolysis also accumulate FDG in cells[ 17 - 21 ]. In essence, FDG demonstrates no discriminatory ability between malignant and benign cells.…”

Section: Characteristics Of F-18 Fdgmentioning

confidence: 99%

Focal incidental colorectal fluorodeoxyglucose uptake: Should it be spotlighted?

Lee,

Hwang

2024

World J Clin Cases

View full text Add to dashboard Cite

Fluorine-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) has emerged as a cornerstone in cancer evaluation imaging, with a well-established history spanning several years. This imaging modality, encompassing the examination of the body from the base of the skull to the upper thighs, comprehensively covers the chest and abdominopelvic regions in a singular scan, allowing for a holistic assessment of nearly the entire body, including areas of marginal interest. The inherent advantage of this expansive scan range lies in its potential to unveil unexpected incidental abnormal hypermetabolic areas. The identification of incidental focal FDG uptake within colorectal regions during PET/CT scans is not an uncommon occurrence, albeit fraught with challenges associated with non-specific FDG uptake. The presence of benign colorectal lesions or physiological uptake poses a particular obstacle, as these may manifest with FDG uptake levels that mimic malignancy. Consequently, physicians are confronted with a diagnostic dilemma when encountering abnormal FDG uptake in unexpected colorectal areas. Existing studies have presented divergent results concerning these uptakes. Standardized uptake value and its derivatives have served as pivotal metrics in quantifying FDG uptake in PET images. In this article, we aim to succinctly explore the distinctive characteristics of FDG, delve into imaging findings, and elucidate the clinical significance of incidental focal colorectal uptake. This discussion aims to contribute valuable insights into the nuanced interpretation of such findings, fostering a comprehensive understanding.

show abstract

18F-FDG gallbladder uptake: observation from a total-body PET/CT scanner

et al. 2023

View full text Add to dashboard Cite

Background Total-body positron emission tomography/computed tomography (PET/CT) scanners are characterized by higher signal collection efficiency and greater spatial resolution compared to conventional scanners, allowing for delayed imaging and improved image quality. These advantages may also lead to better detection of physiological processes that diagnostic imaging professionals should be aware of. The gallbladder (GB) is not usually visualized as an 18F-2-fluorodeoxyglucose (18F-FDG)-avid structure in routine clinical PET/CT studies; however, with the total-body PET/CT, we have been increasingly visualizing GB activity without it being involved in an inflammatory or neoplastic process. The aim of this study was to report visualization rates and characteristics of GB 18F-FDG uptake observed in both healthy and oncological subjects scanned on a total-body PET/CT system. Materials and methods Scans from 73 participants (48 healthy and 25 with newly diagnosed lymphoma) who underwent 18F-FDG total-body PET/CT were retrospectively reviewed. Subjects were scanned at multiple timepoints up to 3 h post-injection. Gallbladder 18F-FDG activity was graded using liver uptake as a reference, and the pattern was qualified as present in the wall, lumen, or both. Participants’ characteristics, such as age, sex, body-mass index, blood glucose, and other clinical parameters, were collected to assess for any significant correlation with GB 18F-FDG uptake. Results All 73 subjects showed GB uptake at one or more imaging timepoints. An increase in uptake intensity overtime was observed up until the 180-min scan, and the visualization rate of GB 18F-FDG uptake was 100% in the 120- and 180-min post-injection scans. GB wall uptake was detected in a significant number of patients (44/73, 60%), especially at early timepoint scans, whereas luminal activity was detected in 71/73 (97%) subjects, especially at later timepoint scans. No significant correlation was found between GB uptake intensity/pattern and subjects’ characteristics. Conclusion The consistent observation of GB 18F-FDG uptake recorded in this study in healthy participants and subjects with a new oncological diagnosis indicates that this is a normal physiologic finding rather than representing an exception.

show abstract

F-18 FDG PET/CT Imaging in Normal Variants, Pitfalls and Artifacts in the Abdomen and Pelvis

Cited by 4 publications

References 19 publications

Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?

Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?

Focal incidental colorectal fluorodeoxyglucose uptake: Should it be spotlighted?

18F-FDG gallbladder uptake: observation from a total-body PET/CT scanner

Contact Info

Product

Resources

About